Tarsus Pharmaceuticals, Inc. (TARS) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $60.52 (-2.15%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Nov 6, 2025 | Andrea Tan | Goldman Sachs | $51.00 | -15.7% |
| May 2, 2025 | Eddie Hickman | Guggenheim | $84.00 | +38.8% |
| Jan 27, 2025 | Balaji Prasad | Barclays | $62.00 | +2.4% |
| Jan 22, 2025 | Francois Brisebois | Oppenheimer | $72.00 | +19.0% |
| Sep 23, 2024 | Francois Brisebois | Oppenheimer | $63.00 | +4.1% |
| May 13, 2024 | Oren Livnat | H.C. Wainwright | $61.00 | +0.8% |
Top Analysts Covering TARS
TARS vs Sector & Market
| Metric | TARS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.40 |
| Analyst Count | 3 | 8 | 19 |
| Target Upside | +9.9% | +11475.0% | +17.1% |
| P/E Ratio | -40.00 | 3.95 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $165M | $169M | $176M | 5 |
| 2026-09-30 | $170M | $175M | $183M | 2 |
| 2026-12-31 | $191M | $197M | $206M | 2 |
| 2027-03-31 | $181M | $186M | $195M | 2 |
| 2027-06-30 | $208M | $215M | $225M | 2 |
| 2027-09-30 | $217M | $223M | $234M | 2 |
| 2027-12-31 | $236M | $243M | $255M | 2 |
| 2028-12-31 | $1.03B | $1.06B | $1.10B | 4 |
| 2029-12-31 | $1.17B | $1.20B | $1.25B | 3 |
| 2030-12-31 | $1.29B | $1.33B | $1.38B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.26 | $-0.15 | $-0.02 | 4 |
| 2026-09-30 | $-0.21 | $-0.19 | $-0.19 | 1 |
| 2026-12-31 | $0.03 | $0.03 | $0.04 | 2 |
| 2027-03-31 | $0.14 | $0.14 | $0.15 | 2 |
| 2027-06-30 | $0.59 | $0.61 | $0.65 | 1 |
| 2027-09-30 | $0.70 | $0.73 | $0.78 | 1 |
| 2027-12-31 | $0.98 | $1.02 | $1.09 | 2 |
| 2028-12-31 | $3.08 | $5.06 | $6.72 | 4 |
| 2029-12-31 | $6.76 | $7.00 | $7.37 | 2 |
| 2030-12-31 | $8.89 | $9.20 | $9.69 | 2 |
Frequently Asked Questions
What is the analyst consensus for TARS?
The consensus among 3 analysts covering Tarsus Pharmaceuticals, Inc. (TARS) is Buy with an average price target of $89.33.
What is the highest price target for TARS?
The highest price target for TARS is $84.00, set by Eddie Hickman at Guggenheim on 2025-05-02.
What is the lowest price target for TARS?
The lowest price target for TARS is $51.00, set by Andrea Tan at Goldman Sachs on 2025-11-06.
How many analysts cover TARS?
3 analysts have issued ratings for Tarsus Pharmaceuticals, Inc. in the past 12 months.
Is TARS a buy or sell right now?
Based on 3 analyst ratings, TARS has a consensus rating of Buy (2.00/5) with a +9.9% upside to the consensus target of $89.33.
What are the earnings estimates for TARS?
Analysts estimate TARS will report EPS of $-0.15 for the period ending 2026-06-30, with revenue estimated at $169M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.